secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0000950170-24-121099
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam reports initial BEAM-101 clinical data: engraftment, HbF >60%, one death from busulfan conditioning
--------------------------------------------------------------------------------

- BEAM-101 (sickle cell disease): 4 patients engrafted, median 17 days neutrophil, 20 days platelet; HbF >60% by month 1.
- BEAM-101: One death from respiratory failure attributed to busulfan conditioning, not BEAM-101; DSMC and FDA reviewed.
- BEAM-201 (T-ALL/T-LL): 2 of 3 patients achieved CRi/CR at doses <200 million cells; both eligible for stem cell transplant.
- ESCAPE NHP data: CD117 mAb conditioning well tolerated; HbF reached ~85% F-cells by 35 weeks in both animals.
- Initial data from BEACON trial also showed no VOCs post-treatment and normalization of hemolysis markers in all 4 evaluable patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017024121099/0000950170-24-121099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017024121099/beam-20241105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-121099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer